Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
TSI extends 2nd battery mixing system supply contract end date to Dec. 31, 2026

TSI extends 2nd battery mixing system supply contract end date to Dec. 31, 2026

BitgetBitget2026/10/02 07:22
  • TSI corrected its sales-supply contract disclosure, extending the contract end date to 2026-12-31 from 2026-10-06.
  • The change also extends the disclosure hold period to 2026-12-31 from 2026-10-06.
  • The contract covers a secondary-battery mixing system worth KRW 27.51 billion, equal to 10.1% of 2024 consolidated revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TSI Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261002900723), on October 02, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar

Deutsche Bank believes that the continuously expanding chip trade surplus in Asia is becoming a supporting force for the US dollar, as related profits are increasingly being reinvested into the US stock market.

智通财经•2026/11/16 23:03
The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar

Roche's (RHHBY.US) new breast cancer drug Wilserdly approved by FDA: Analysts predict peak annual sales could reach up to $14.5 billion

Roche's (RHHBY.US) new oral breast cancer drug has been approved by U.S. regulators, paving the way for this medication, which the pharmaceutical company hopes will transform the treatment of the disease.

智通财经•2026/11/16 22:53